Listar por autor "Esteban, Emilio"

Mostrando ítems 1-3 de 3

    • Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program 

      Castellano, Daniel; Antón-Aparicio, Luis M.; Esteban, Emilio; Sánchez-Hernández, Alfredo; Germá, José Ramón; Batista, Norberto; Maroto, Pablo; Pérez-Valderrama, Begoña; Luque, Raquel; Méndez-Vidal, María José (Taylor & Francis, 2014-07-07)
      [Abstract] BACKGROUND: Based on the TROPIC study results, cabazitaxel was approved for the management of metastatic castration-resistant prostate cancer (mCRPC) progressing on or after docetaxel. METHODS: This multi-centre ...

    • Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies 

      Castellano, Daniel; Maroto, José Pablo; Espinosa, Enrique; Grande, Enrique; Bolós Fernández, Victoria; Llinares, Julia; Esteban, Emilio; González del Alba, Aránzazu; Climent, Miguel Ángel; Arranz, José Ángel; Méndez, María José; Fernández Parra, Eva; Antón-Aparicio, Luis M.; Bayona, Cristina; Gallegos, Isabel; Gallardo, Enrique; Samaniego, Luz; García Donas, Jesús (Taylor & Francis, 2017-08-28)
      [Abstract] Background: A pivotal, randomized, phase III trial demonstrated a statistically significant superiority of sunitinib over interferon-α in metastatic renal cell carcinoma (mRCC) patients. Objective: To evaluate ...

    • Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma 

      Puente, Javier; Lainez, Nuria; Dueñas, Marta; Méndez-Vidal, María José; Esteban, Emilio; Castellano, Daniel; Martínez-Fernández, Mónica; Basterretxea, Laura; Juan-Fita, María José; Antón-Aparicio, Luis M.; León, Luis; Lambea, Julio; Pérez-Valderrama, Begoña; Vázquez, Sergio; Suárez, Cristina; García del Muro, Xavier; Gallardo, Enrique; Maroto, José Pablo; Samaniego, M. Luz; Suárez-Paniagua, Beatriz; Sanz, Julián; Paramio, Jesús M. (Impact Journals, 2017-03-23)
      [Abstract] Background: Several potential predictive markers of efficacy of targeted agents in patients with metastatic renal cell carcinoma (mRCC) have been identified. Interindividual heterogeneity warrants further ...